Johanna Rossell

CCO at Enzyvant Therapeutics

Johanna Rossell is the Chief Commercial Officer at Enzyant. She leads their commercial enterprise including the U.S. commercialization of RETHYMIC®. She has an extensive background in the pharmaceutical and healthcare sector, leading multifunctional teams in the US and across several geographic markets around the world. She has led teams to deliver strong business results for companies such as Novartis, Merck, Mallinckrodt, and Biogen, with a robust track record of bringing new products to market and creating integrated pre-and post-launch commercial plans including a Regenerative Medicine Advanced Therapy (RMAT)-designated tissue-based product and several therapies for rare diseases.